Navigation Links
Santarus to Webcast Analyst Day and Investor Briefing Presentation on January 19
Date:1/19/2011

SAN DIEGO, Jan. 19, 2011 /PRNewswire/ -- Santarus, Inc. (Nasdaq: SNTS) announces that a live audio webcast and accompanying slide presentation will be provided for its Analyst Day and Investor Briefing.  

Details of the event are as follows:What:Santarus Analyst Day and Investor BriefingWhen:Today, Wednesday, January 19, 2011 at 4:15 p.m. Eastern timeWhere:www.santarus.com (under the Investor Relations link)AGENDA

  • Strategic Overview and 2011 Financial Outlook


  • Gerald T. Proehl, President, Chief Executive Officer & Director, Santarus, Inc.

  • CYCLOSET® - Clinical/Medical Background


  • Dr. J. Michael Gaziano, Chief, Division of Aging, Brigham & Women’s Hospital,


    Professor of Medicine, Harvard Medical School

  • ULTESA™ (Budesonide MMX®) – Overview and Top-line Phase III Clinical Study Results


  • Dr. Simon P.L. Travis, Consultant Gastroenterologist,


    Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK

  • Ulcerative Colitis – Treatment Perspective


  • Dr. William J. Sandborn, Professor of Clinical Medicine and Chief of the Division of Gastroenterology,


    University of California, San Diego

  • RHUCIN® and Hereditary Angioedema (HAE)


  • Dr. Bruce L. Zuraw, Professor of Medicine and Chief, Allergy and Immunology, University of California, San Diego,


    Research Scientist, San Diego VA Healthcare

  • SAN-300 (anti-VLA-1 antibody)


  • Dr. Mark C. Totoritis, Senior Vice President, Biologics, Santarus, Inc.

  • Wrap-up/Question & Answer Session


  • Gerald T. Proehl, President, Chief Executive Officer & Director, Santarus, Inc.

    How:Live over the Internet – Simply log on to the Investor Relations section of the company's website at www.santarus.comContact:Lippert/Heilshorn & AssociatesNarine Darbinyan310-691-7100About SantarusSantarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists.  The company's current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes.  

    Santarus also has a diverse development pipeline with three late-stage product candidates in Phase III clinical programs:  ULTESA™ (budesonide MMX®) for induction of remission of active ulcerative colitis, RHUCIN® (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema and rifamycin SV MMX® for treatment of travelers' diarrhea.  In addition, Santarus plans to initiate a Phase I clinical study in the first half of 2011 with SAN-300, its anti-VLA-1 antibody, which the company expects to investigate for the treatment of rheumatoid arthritis.  

    Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.  The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans will be achieved.  Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarus' business, including, without limitation:  difficulties or delays in development, testing, manufacturing and marketing of, and obtaining and maintaining regulatory approvals for, Santarus' products; and other risks detailed in Santarus' prior press releases as well as in public periodic filings with the Securities and Exchange Commission.

    You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.  This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    Santarus® and ULTESA™ are trademarks of Santarus, Inc. GLUMETZA® is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc. CYCLOSET® is a trademark of VeroScience LLC. MMX® is a trademark of Cosmo Technologies Limited. RHUCIN® is a trademark of Pharming Group NV.


    '/>"/>

    SOURCE Santarus, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Fourth Quarter and Year End 2010 Results
    2. ResMed Announces Conference Call and Webcast to Discuss Second Quarter 2011 Results
    3. Hill-Rom Holdings, Inc. Hosts Fiscal 2011 First Quarter Earnings Webcast
    4. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
    5. BD Announces Webcast of Annual Meeting of Shareholders
    6. Dendreon Announces Webcast Presentation at J.P. Morgan Healthcare Conference
    7. Thoratec Presentation at J.P. Morgan Conference to Be Webcast
    8. Mettler-Toledo International Inc. Announces Webcast of Presentation at J.P. Morgan Healthcare Conference
    9. Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Advances in its Development Pipeline
    10. Cepheid to Webcast Upcoming Financial Presentation
    11. Webcast Alert: Heska Corporations Special Meeting of Stockholders Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
    (Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
    (Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
    Breaking Medicine Technology:
    (Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
    (Date:4/28/2017)... Md. (PRWEB) , ... April 28, 2017 , ... ... Association of America (UCAOA) and College of Urgent Care Medicine will host industry ... workshops, sessions and speakers will help those in the industry adapt to the ...
    (Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
    (Date:4/28/2017)... ... 28, 2017 , ... Rob Lowe is a popular actor that has been ... to an educational purpose as the host of the “Informed” series. The program focuses ... recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is an ...
    (Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying ... will rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare executive ... executive resume and wondering if it’s as ready as you are for a new ...
    Breaking Medicine News(10 mins):